No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
Bezafibrate |
Bezafibrate |
D01366 |
[1] PPARA |
[7] Adipocytokine signaling pathway, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease (NAFLD), PPAR signaling pathway, cAMP signaling pathway |
[5] 20, 93, 94, 160, 316 |
2 |
Bezafibrate (drug) |
Bezafibrate |
D01366 |
[1] PPARA |
[7] Adipocytokine signaling pathway, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease (NAFLD), PPAR signaling pathway, cAMP signaling pathway |
[1] 316 |
3 |
Break in l-carnitine treatment |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
[1] 316 |
4 |
Carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
[8] 5, 13, 58, 96, 97, 265, 298, 316 |
5 |
Glycerol |
Glycerin |
D00028 |
- |
- |
[4] 6, 13, 316, 317 |
6 |
Glycerol/saline |
Glycerin |
D00028 |
- |
- |
[2] 316, 317 |
7 |
Heparin |
Heparin |
D07510 |
[1] SERPINC1 |
[1] Complement and coagulation cascades |
[11] 60, 70, 79, 84, 107, 224, 226, 280, 299, 316, 317 |
8 |
Hyperinsulinemic euglycemic clamp |
- |
- |
- |
- |
[2] 316, 317 |
9 |
Intralipid/heparin |
Heparin |
D07510 |
[1] SERPINC1 |
[1] Complement and coagulation cascades |
[2] 316, 317 |
10 |
L-carnitine |
Levocarnitine |
D02030, D02176, D04713 |
- |
- |
[6] 13, 96, 97, 265, 298, 316 |